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Neutrophils infected with Mycobacterium tuberculosis (Mtb) predominate in tuberculosis 
patients’ lungs. Neutrophils phagocytose the pathogen, but the mechanism of pathogen 
elimination is controversial. Macroautophagy/autophagy, a crucial mechanism for several 
neutrophil functions, can be modulated by immunological mediators. The costimulatory 
molecule SLAMF1 can act as a microbial sensor in macrophages being also able to interact 
with autophagy-related proteins. Here, we demonstrate for the first time that human 
neutrophils express SLAMF1 upon Mtb-stimulation. Furthermore, SLAMF1 was found 
colocalizing with LC3B+ vesicles, and activation of SLAMF1 increased neutrophil autophagy 
induced by Mtb. Finally, tuberculosis patients’ neutrophils displayed reduced levels of 
SLAMF1 and lower levels of autophagy against Mtb as compared to healthy controls. 
Altogether, these results indicate that SLAMF1 participates in neutrophil autophagy during 
active tuberculosis. 
Abbreviations. AFB: acid-fast bacilli; BafA1: bafilomycin A1; CLL: chronic lymphocytic 
leukemia; DPI: diphenyleneiodonium; EVs: extracellular vesicles; FBS: fetal bovine serum; 
HD: healthy donors; HR: high responder (tuberculosis patient); IFNG: interferon gamma; 
IL1B: interleukin 1 beta; IL17A: interleukin 17A; IL8: interleukin 8; LR: low responder 
(tuberculosis patient); mAb: monoclonal antibody; MAP1LC3/LC3: microtubule associated 
protein 1 light chain 3; MAPK: mitogen-activated protein kinase;  MAPK1/ERK2: mitogen-
activated protein kinase 1;  MAPK14/p38: mitogen-activated protein kinase 14; Mtb: 
Mycobacterium tuberculosis; Mtb-Ag: Mycobacterium tuberculosis, Strain H37Rv, whole 
cell lysate; NETs: neutrophils extracellular traps; PPD: purified protein derivative; ROS: 











3;  SLAMF1: signaling lymphocytic activation molecule family member 1; TB: tuberculosis; 
TLR: toll like receptor.  
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Introduction 
Tuberculosis (TB) is the leading cause of death from an infectious microorganism. Actually, 
Mycobacterium tuberculosis (Mtb) produces nearly 10 million new cases and 1.5 million 
deaths per year [1]. The successful establishment of Mtb infection depends on its primary 
interaction with host macrophages, dendritic cells, neutrophils and NK cells [2]. Although 
great progresses have been made in the characterization of the acquired cellular responses in 
TB patients, it remains to be elucidated what exactly constitutes a protective response [3].  
Furthermore, how Mtb is able to evade host immune surveillance and persist, particularly 
inside phagocytes, remains to be completely understood. 
 Neutrophils arrive first at the site of infection and are the cells predominantly infected 
with Mtb in patients’ lungs [4]. Neutrophils’ ability to phagocytose Mtb has been 
demonstrated but its capacity to eliminate the bacteria remains controversial. These cells can 
sequester Mtb in neutrophils extracellular traps (NETs) [5]; cooperate with other cells 
and release extracellular vesicles (EVs) upon activation. Particularly, EVs charged 
with Mtb activate macrophages, promoting autophagy induction and Mtb clearance [6]. 
However, many studies agree about the fact that neutrophils trigger a hyper-inflammatory 
response that leads to tissue destruction and mediates damage and lung disease during active 
TB. In fact, human blood transcriptional profiling performed in TB patients indicated that the 
TB signature was dominated by a neutrophil-driven interferon (IFN)-inducible gene profile, 
reflecting the central participation of these cells in active disease [7]. Therefore, a deeper 
investigation into the biology of neutrophils during Mtb infection is crucial for the 











Macroautophagy/autophagy is a central homeostatic mechanism that plays a role in 
innate and adaptive immunity against intracellular pathogens, including Mtb [8]. 
Furthermore, in macrophages, enhanced autophagy mediates elimination of intracellular Mtb 
through lytic and antimicrobial properties unique to autolysosomes [9]. Additionally, it has 
been demonstrated that host autophagy coordinates successful antimicrobial responses to 
mycobacteria during chemotherapy [10]. Moreover, autophagy is essential for major 
neutrophil functions, including degranulation, reactive oxygen species (ROS) production, and 
release of NETs [11]. 
It has also been reported that autophagy can be modulated by different immunological 
mediators [12]. Accordingly, we have demonstrated that IFNG and IL17A regulate 
autophagy in Mtb-infected monocytes from TB patients in correlation with disease severity 
[13,14]. SLAMF1 (signaling lymphocytic activation molecule family member 1), a type I 
glycoprotein from the SLAM subfamily of the CD2-like family of proteins, is a costimulatory 
molecule involved in host immunity regulation of innate and adaptive responses. We have 
demonstrated that SLAMF1 contributes to Th1 cytokine responses in human TB [15]. 
However, SLAMF1 is not only a costimulatory molecule but also a bacterial sensor that helps 
to remove Gram-negative bacteria by macrophages [16]. Actually, after entering the 
phagosome by interaction with bacterial outer proteins, SLAMF1 recruits several molecules 
to the phagosome, including the autophagic protein BECN1/Beclin-1, thus making the 
connection to the cellular machinery that controls bacterial killing [16,17]. Interestingly, it 
has been recently shown that SLAMF1 regulates autophagy in B cells from chronic 
lymphocytic leukemia (CLL) patients, affecting CLL cells responses to autophagy-activating 
therapeutic agents [18]. However, the expression of SLAMF1 in human neutrophils and its 
function during autophagy in these cells have not been previously demonstrated. Therefore, 











studied the participation of SLAMF1 as a regulator of the autophagy process in neutrophils 












Initially, we analyzed the frequency of neutrophils in peripheral blood from patients 
with active TB. Our results indicated that the number of neutrophils was significantly higher 
in patients with severe radiological lesions (bilateral and massive affectation with multiple 
cavities) as compared to patients with moderate lesions (Fig. 1A). Previously we 
demonstrated that TB patients could be classified based on in vitro lymphocyte responses to 
Mtb antigens. Briefly, high responder (HR) patients are individuals displaying significant 
proliferative responses, IFNG production and an increased SLAMF1 expression on T 
lymphocytes upon sonicated Mtb antigen (Mtb-Ag) stimulation, whereas low responder (LR) 
patients exhibit low proliferative responses, IFNG production and SLAMF1 expression.  
Furthermore, LR patients have a more severe pulmonary disease, lower leukocyte counts and 
a more prolonged illness, compared to HR individuals [15]. Nevertheless, when we examined 
the number of neutrophils in high and low responder TB patients, similar number of these 
cells were detected (Fig. 1B). Additionally; we observed a marked increase in neutrophil 
counts in patients with acid-fast bacilli (AFB)-positive smears (Fig. 1C) as well as a positive 
correlation between the number of neutrophils and the time of disease evolution (Fig. 1D). 
Consistent with previous reports [19-21], our findings suggest that increasing numbers of 
neutrophils might contribute to TB severity. In fact, it was reported that TB cavities contain 
more neutrophils and less lymphocytes compared to nondestructive pulmonary infiltrates and 
radiologically unaffected lobes of the lungs [19]. Moreover, we observed that patients 
undergoing advanced stages of anti-TB treatment displayed lower numbers of neutrophils 
than those undertaking the first week of chemotherapy (6714 ± 468 neutrophils vs. 5657 ± 
710 neutrophils, respectively).  
SLAMF1 expression has been demonstrated not only in lymphocytes but in myeloid 











human neutrophils has not been evaluated so far. Thus, we initially performed bioinformatic 
analysis finding evidence of SLAMF1 RNA expression in unstimulated mature neutrophils 
from healthy donors (HD) and TB patients (Fig. S1A, B). In line with those initial analyses, 
in this work, we observed the presence of SLAMF1 in neutrophils from HD and TB patients 
both by confocal microscopy (Fig. 2A) and flow cytometry (Fig. 2C). Furthermore, after 2 h 
of Mtb-Ag stimulation, we detected an increase in SLAMF1 levels on neutrophils’ membrane 
(Fig. 2B) and an accumulation of localized signal at the intracellular level (Fig. 2A). In fact, 
Ag challenge significantly elevated the percentage of SLAMF1+ neutrophils as detected by 
flow cytometry (Fig. 2B-D). Interestingly, upon Mtb-Ag stimulation, HD displayed greater 
percentages of SLAMF1+ neutrophils as compared to TB patients (Fig. 2C and Fig. S2A). 
Thus, these results show for the first time to our knowledge that SLAMF1 is expressed in 
human neutrophils and that it increases upon Mtb-Ag stimulation. Notably, comparable 
elevated surface levels of SLAMF1 were detected in both subjects’ populations after a robust 
neutrophil activation with phorbol myristate acetate/PMA (Fig. S2B). 
 In order to determine the nature of the mycobacterial components involved in the 
induction of SLAMF1 surface expression on neutrophils, we compared SLAMF1 levels after 
stimulation with various stimuli. Interestingly, the highest levels of SLAMF1 were induced 
by compounds that included several proteins, such as purified protein derivative (PPD, Fig. 
3A) or culture filtrate proteins (data not shown). Single proteins such as ESAT-6 or CFP-10 
did not induce significant amounts of SLAMF1. Moreover, total Mtb lipids induced a 
moderate proportion of SLAMF1+ neutrophils (Fig. 3A). Furthermore, additional antigens 
with different chemical compositions, such as the lipoglycan ManLam or the 19-kDa Mtb 
lipoglycoprotein (also known as LpqH), both significantly increased the percentage of 
SLAMF1+ neutrophils as well, in comparison with non-stimulated cells (Fig. 3A). Altogether, 











neutrophils during Mtb-Ag stimulation and induce SLAMF1 surface expression. In particular, 
compounds including several proteins or lipo/glycans, acted as the predominant stimulators 
of SLAMF1 expression on human neutrophils.  
 MAPKs (mitogen-activated protein kinases) have been described to be involved in 
SLAMF1 expression in lipopolysaccharide (LPS)-stimulated monocytes [23]. Thus, to get 
insight into the molecular mechanisms that lead to SLAMF1 surface expression on human 
neutrophils, we next investigated the potential role of the MAPK14/p38 and MAPK1/ERK2-
MAPK3/ERK1 pathways. Purified cells were pre-incubated with PD98059 or SB202190 
inhibitors for 30 min, and then those neutrophils were stimulated with Mtb-Ag for an 
additional 2 h.  Afterwards, SLAMF1 expression was evaluated by flow cytometry. As shown 
in Figure 3B, the analysis clearly revealed that inhibition of both MAPK/ERK and 
MAPK14/p38 kinases significantly diminished the percentage of SLAMF1+ neutrophils upon 
antigen stimulation. Therefore, these findings suggest that these MAPKs participate in the 
signaling pathway that triggers SLAMF1 surface expression on Mtb-Ag-stimulated 
neutrophils. 
 Oxidants produced upon NOX (NADPH oxidase) activation play a central role in 
diverse neutrophil functions [24,25].  Thus, we then analyzed their possible participation in 
SLAMF1 surface expression. Purified neutrophils were stimulated with or without Mtb-Ag in 
the presence or absence of the NOX inhibitor diphenyleneiodonium (DPI) and, after 2 h, 
SLAMF1 expression was evaluated using flow cytometry. As shown in Figure 3C, inhibition 
of reactive oxygen species (ROS) generation significantly diminished the percentage of 
SLAMF1+ neutrophils. Therefore, our results suggest that expression of SLAMF1 in Mtb-Ag-
stimulated neutrophils is dependent on ROS production. 
 Recently, Bologna et al reported that reduced SLAMF1 expression in B 











Additionally, the interaction of SLAMF1 with PIK3C3/VPS34 and BECN1, two proteins 
involved in the initiation of the autophagy process, had previously been described [16]. In the 
present work, we observed that Mtb-Ag stimulation significantly augmented the percentage 
of MAP1LC3A/B-II/LC3A/B-II+ neutrophils from TB patients and HD (Fig. 4A), denoting 
the presence of more autophagosomes by the recognition of mycobacterial antigens. Given 
that autophagy is a dynamic process and a proportion of autophagosome-anchored-LC3-II is 
degraded when it reaches the lysosome, the autophagy flux in the presence or absence of 
bafilomycin A1 (Baf A1) was analyzed.  It is important to notice that the observed increment 
corresponds to an elevated autophagic flux (Fig. S3A), as showed by a significant increase in 
the percentage of Mtb-Ag-stimulated LC3A/B-II+ neutrophils treated with Baf A1 compared 
with cells stimulated with Mtb-Ag alone. Interestingly, we detected significantly greater 
autophagy levels in neutrophils from HD as compared to neutrophils from TB patients (Fig. 
4A). Moreover, we observed that HR TB patients’ neutrophils displayed elevated autophagy 
levels in comparison to LR TB patients’ cells (Fig. S3B). 
Considering our data showing expression of SLAMF1 on Mtb-stimulated neutrophils, 
we next evaluated the potential role of this molecule during the autophagy process in 
neutrophils from TB patients. Isolated neutrophils were stimulated with Mtb-Ag and, at the 
same time, cultured in the presence or absence of an agonistic anti-SLAMF1 antibody. As 
shown in Figure 4B, we were able to confirm by confocal microscopy an accumulation of 
localized LC3B foci in Mtb-Ag-treated neutrophils. Moreover, activation of SLAMF1 in Ag-
stimulated neutrophils significantly increased endogenous LC3B aggregation (Fig. 4B). 
Furthermore, stimulation with anti-SLAMF1 significantly augmented the percentage of 
LC3A/B-II+ neutrophils as measured by flow cytometry (Fig. 4C). Importantly, treatment of 
neutrophils from TB patients with anti-SLAMF1 in the absence of Mtb-Ag had no effect on 











We next investigated the autophagy flux in the presence or absence of Baf A1. Anti-
SLAMF1 significantly increased LC3B puncta/cell levels in neutrophils from TB patients 
stimulated with Mtb-Ag when Baf A1 was present in the culture (Fig. 4D), suggesting that 
SLAMF1 activation induces autophagosome formation and a functional autophagy pathway. 
Furthermore, to support that SLAMF1 regulates autophagy in neutrophils, and because 
neutrophils are terminally differentiated cells that cannot be transfected, we silenced 
SLAMF1 by using PLB985 cells, a human myeloid cell line that can be differentiated to a 
neutrophilic profile. Notably, SLAMF1 silencing markedly reduced the percentage of LC3A/ 
B-II+ cells as compared to PLB985 cells transfected with non-targeting siRNA when 
stimulated with Mtb-Ag (data not shown).  
In addition, a positive correlation between the percentage of SLAMF1+ neutrophils 
and LC3A/B-II+ cells was found (Fig. S4A), further reinforcing the potential role of 
SLAMF1 during neutrophil autophagy in TB patients. Moreover, we performed a flow 
cytometry analysis in Mtb-Ag-stimulated neutrophils by gating on SLAMF1+ and SLAMF1- 
cells. This analysis revealed that autophagy levels detected after Mtb-Ag stimulation were 
mainly observed in SLAMF1+ cells (Fig. S4B). Besides, we observed colocalization of LC3B 
and SLAMF1 in Mtb-Ag-stimulated neutrophils (Fig. 4E). These findings suggest that upon 
neutrophil activation by Mtb-Ag, the triggering of autophagy flux would lead SLAMF1 to 
LC3+ vesicles.  
Considering that ROS are critical intracellular signal transducers sustaining autophagy 
[26] and our results described above, we next investigated the intracellular levels of ROS 
upon SLAMF1 activation. As shown in Figure 5A, Mtb-Ag triggered ROS production. 
Moreover, signaling through SLAMF1 in Mtb-stimulated neutrophils significantly increased 











that ROS are required for the increase in SLAMF1 membrane expression, and, in turn, 
SLAMF1 activation promotes ROS production induced by Mtb-Ag stimulation.     
Because the membrane expression of SLAMF1 induced by Mtb-Ag was dependent on 
ROS production (Fig. 3C) and taking into account that SLAMF1 activation enhanced 
neutrophil autophagy induced by Mtb-Ag (Fig. 4), we then reasoned that DPI should inhibit 
the increase in autophagy levels upon SLAMF1 stimulation. To test this possibility, HD’s 
neutrophils were treated or not with DPI and then these cells were stimulated with Mtb-Ag ± 
anti-SLAMF1. Finally, autophagy levels were determined. Figure 5B shows that inhibition 
of ROS generation did not modulate autophagy levels in Mtb-Ag-stimulated cells but 
abrogated the increase in the percentage of LC3A/B-II+ cells observed when neutrophils 
were stimulated simultaneously with Mtb-Ag and anti-SLAMF1. These results, together with 
those shown in Fig. 4 and Fig. S4A (showing the correlation between SLAMF1 levels and 
the percentage of LC3A/B-II+ neutrophils), further support the idea that SLAMF1 regulates 












The outcome of Mtb infection depends on the capacity of the host to develop an effective 
immunity together with its ability to balance the inflammatory responses. Neutrophils 
participate in granuloma formation but they also mediate tissue destruction and disease 
severity [27]. These cells appear as multi-functional leukocytes with variable roles in host 
defense. In fact, the existence of a duality between neutrophils’ ability to clear Mtb infection 
and the contribution of increasing numbers of these cells to TB severity and mortality has 
been documented [20].  
SLAMF1 is a self-ligand costimulator that activates lymphocytes. We previously 
demonstrated that SLAMF1 expression on TB patients’ T cells correlates with responsiveness 
to Mtb-Ag [15]. Most members of the SLAM subfamily are expressed on myeloid cells such 
as macrophages and monocytes [17], but the expression of SLAMF1 in neutrophils has not 
been reported. In this work we demonstrated that Mtb-stimulation significantly induced 
SLAMF1 expression on human neutrophils. Moreover, we observed that diverse 
mycobacterial components might be recognized by human neutrophils during stimulation 
with Mtb-Ag and induce SLAMF1 surface expression. In particular, multiple-protein or 
lipo/glycans compounds were found as the predominant stimulators of SLAMF1 expression 
(Fig. 3A). These findings are in line with the reported increased SLAMF1 expression on 
monocytes and macrophages by various toll like receptor (TLR) ligands such as Pam3Cys 
(TLR1-TLR2), synthetic FSL-1 (TLR2-TLR6), LTA and PGN from Staphylococcus aureus 
(TLR2), flagellin (TLR5) and R848 (TLR7 and TLR8)[23,28]. Indeed, for example, both 
TLR1-TLR2 and TLR2-TLR6 bind to ManLam [29,30] lipoglycan a major well-
characterized Mtb virulence factor that regulates the intracellular trafficking network and the 
immune response of the infected host cell. Nevertheless, recognition by other types of 











Additionally, by using MAPK14/p38 and MAP2K/MEK-MAPK/ERK inhibitors we 
demonstrated that these MAPKs participate in the signaling pathway induced by Mtb-Ag that 
leads to SLAMF1 surface expression on neutrophils (Fig. 3B). Previously, Farina et al. have 
described the participation of MAPK14/p38 signaling during transient SLAMF1 expression 
on LPS-stimulated monocytes [23]. Besides, Boggaram et al reported that ESAT-6, a protein 
secreted by Mtb, induces the expression of IL8 in lung epithelial cells by activating 
MAPK/ERK and MAPK14/p38 and a rapid induction of ROS production [31]. Moreover, we 
found that NOX inhibition significantly diminished the percentage of SLAMF1+ neutrophils 
(Fig. 3C), suggesting that expression of SLAMF1 in response to Mtb is dependent on ROS 
production.  
Of further interest was the fact that Mtb-Ag-stimulation induced higher numbers of 
SLAMF1+ neutrophils in HD than in TB patients (Fig. 2C). We have previously reported that 
Mtb-Ag-stimulation induced significantly lower levels of SLAMF1 in T lymphocytes from 
TB patients as compared to HD [15]. In fact, we observed the highest levels of SLAMF1 in T 
cells from HD and the lowest levels of the protein in TB patients with the poorest immune 
response to Mtb-Ag (LR TB patients) [15]. Besides, as mentioned previously, Bologna et al 
have reported altered expression of SLAMF1 levels in cells from patients with CLL [18]. In 
particular, they found that SLAMF1 is lost in CLL cells of patients characterized by a shorter 
overall survival. Therefore, considering all these previous studies, the reduced levels of 
SLAMF1 found in neutrophils from TB patients as compared to HD, might be related to 
imbalances of costimulatory molecules during certain human pathologies [15,18,32-34]. 
Furthermore, it was suggested that TB disease dramatically alters neutrophils, leading to the 
accumulation of heterogeneous subpopulations of immature and activated dysfunctional cells 
[27,35,36], although their occurrence during human TB and the role of SLAMF1 remains to 











influence the pathology and the immune responses against Mtb [37-42]. Indeed, single 
nucleotide polymorphisms may influence the differential SLAMF1 expression on neutrophils 
from TB patients and HD.  
 Previous studies showed that SLAMF receptors react with self-proteins, measles 
virus proteins and bacterial proteins. Additionally, it was shown that SLAMF1 also interacts 
with the PIK3C3/VPS34-BECN1-UVRAG complex involved in autophagosome maturation 
[17], and supports phagosome maturation by using the ubiquitous autophagy machinery [16]. 
Moreover, SLAMF1 was reported to regulate an intracellular autophagic pathway. Actually, 
SLAMF1 ligation with a monoclonal antibody increases ROS accumulation and induces 
MAPK14/p38, MAPK8/JNK1-MAPK9/JNK2 and BCL2 phosphorylation, promoting 
autophagic flux in B cells [18]. However, the role of SLAMF1 as a regulator of autophagy in 
the context of immunity against Mtb has not been described. Here we demonstrated that Mtb-
Ag induced autophagy in human neutrophils from patients undergoing active TB; and 
SLAMF1 ligation further increased autophagy in these cells. In fact, a positive correlation 
between the percentage of surface SLAMF1+ neutrophils and LC3A/B-II+ cells was found, 
further reinforcing the potential role of SLAMF1 during neutrophil autophagy in TB patients.  
Our findings indicated that the increased SLAMF1 expression induced by Mtb 
involves the MAPKs MAPK14/p38 and MAPK/ERK and NADPH-dependent ROS 
production. Accordingly, the inhibition of NADPH, by impairing SLAMF1 upregulation, 
abrogated the increase in autophagy observed upon SLAMF1 ligation in Mtb-stimulated cells. 
These findings, together with the fact that only SLAMF1-expressing neutrophils from TB 
patients underwent detectable autophagy levels, and the positive correlation found between 
neutrophil SLAMF1 expression and autophagy levels, support the role of SLAMF1 in 
regulating neutrophil autophagy upon Mtb stimulation. Interestingly, as reported by Bologna 











production. If these ROS further modulate SLAMF1 expression at later time points remains 
to be determined.    
Most of the studies on mycobacterium-triggered autophagy were performed in mouse 
model cell lines or HD primary culture cells, but very limited information exists about 
autophagy in TB patients. Actually, we showed that Mtb-induced IFNG regulates autophagy 
in TB patients’ cells [13]. Consequently, an important aspect of our study is the investigation 
of autophagy in neutrophils from patients with active TB. 
 Interestingly, we observed a significant decrease of autophagy levels in neutrophils 
from TB patients as compared to HD.  Because TB patient’s displayed lower levels of 
SLAMF1 as compared to HD, our findings are in agreement with those previously reported in 
CLL patients, which showed that CLL SLAMF1– cells exhibit an impairment in autophagy 
activation [18]. Moreover, we further detected a direct correlation between neutrophil 
numbers and the severity of the disease, as previously demonstrated by other authors [19-21]. 
In fact, it was reported that TB cavities contain more neutrophils and less lymphocytes 
compared to nondestructive pulmonary infiltrates and radiological unaffected lobes of the 
lungs [19]. Hence, considering that autophagy protects against excessive inflammation 
during Mtb infection [43], the reduced autophagy detected in patients’ neutrophils might 
be associated to the common detrimental inflammatory responses occurring during active 
disease.   
Thus, published results [16,18] together with our present findings suggest that 
SLAMF1 constitutes a human regulator of the autophagy process. Then, if autophagy 
prevents over-exuberant inflammation, it could be a target for clinical purposes [43]. 
Therefore, both neutrophil autophagy and SLAMF1 emerge as attractive targets for host-
directed therapies either directly increasing the ability of the host to eliminate mycobacteria 











suppress the activation of several inflammasomes by multiple mechanisms but we 
demonstrated that it also mediates neutrophil IL1B unconventional-secretion [44], further 
investigations are underway to elucidate the functional consequences of this event. 
In conclusion, we identified SLAMF1 as an innate receptor in human neutrophils that 
can regulate cellular responses against Mtb. Therefore, either inducing autophagy in myeloid 
cells or increasing Th1 responses, SLAMF1 would be a key receptor in human immunity 
against Mtb. Whether SLAMF1 might participate in clinical outcome affecting drug 
responses of TB patients remains to be elucidated. Altogether, our findings suggest that 
stimulation of SLAMF1 promotes neutrophil autophagy induced by Mtb, suggesting that it 














Material and Methods 
Subjects.  
HIV-uninfected patients with TB were diagnosed at the Servicio de Tisioneumonología 
Hospital F.J. Muñiz, Buenos Aires, Argentina, based on clinical and radiological data, 
together with the identification of acid-fast bacilli in sputum. All participating patients had 
received less than 1 week of anti-TB regular therapy. Table 1 summarizes the demographic 
and clinical characteristics of enrolled TB patients. Bacillus Calmette-Guerin (BCG)-
vaccinated healthy control individuals (HD) from the community participated in this study. 
Peripheral blood was collected in heparinized tubes from each participant after obtaining 
informed consent. The local Ethics Committee approved all studies.  
Exclusion criteria and patient classification.  
All subjects were 18-60 years old and had no history of illnesses that affect the immune 
system, such as HIV infection, a recent diagnosis of cancer, treatment with 
immunosuppressive drugs, hepatic or renal disease, pregnancy, or positive serology for other 
viral (e.g., hepatitis A, B or C), or bacterial (e.g., leprosy, syphilis) infections. Individuals 
with bleeding disorders or under anticoagulant medication that might be at an increased risk 
of bleeding during the procedure of obtaining the sample were excluded from the study. 
Individuals with latent infection were excluded from the present study by using the 
QuantiFERON-TB® GOLD PLUS kit (Qiagen, 622120 and 622526). TB patients were 
classified as high-responder (HR) or low responder patients (LR) as previously reported [15], 
based on in vitro lymphocyte responses to sonicated M. tuberculosis antigen (Mtb-Ag). 
Briefly, HR patients are individuals displaying significant proliferative responses, IFNG 
production and an increased SLAMF1 expression against the antigen; whereas LR patients 











had more severe pulmonary disease, lower leukocyte counts, and a more prolonged illness, 
compared to HR individuals [15]. 
Antigen.  
In vitro stimulation of cells was performed with a cell lysate from the virulent 
Mycobacterium tuberculosis strain H37Rv, prepared by probe sonication (Mtb-Ag) (BEI 
Resources, NIAID, NIH: Mycobacterium tuberculosis, Strain H37Rv, whole cell lysate, NR-
14822). 
Cell preparations and culture conditions.  
Neutrophils were isolated from heparinized blood by centrifugation on Ficoll-Paque (GE 
Healthcare, 17-1440-03), dextran sedimentation, and hypotonic lysis [45]. Cells were 
suspended at 2 × 106 /mL in RPMI 1640 (Invitrogen, 22400071) supplemented with L-
glutamine (2 mM; Sigma Aldrich, G6392), penicillin (100 U/mL; Gibco, 15140122), 
streptomycin (100 µg/mL; Gibco, 15140122), and 10% fetal bovine serum (FBS; Gibco, 
10437028) and used immediately after isolation. Neutrophils were stimulated with Mtb-Ag 
(BEI Resources, NIH, 10 μg/ml) ± anti-SLAMF1 mAb (10 µg/ml, A12; Biolegend, 306310). 
In some experiments, bafilomycin A1 (100 nM; Fermentek, 88899-55-2), 
diphenyleneiodonium chloride (DPI, 100 nM; Sigma Aldrich, 4673-26-1), PD98059 (50 µM; 
Invivogen, tlrl-pd98) or SB202190 (10 µM; Sigma Aldrich, S7067) were added in different 
time points of culture.  
Purity and viability of neutrophils.  
After isolation, neutrophil preparations were stained with an anti-CD14-PE (Biolegend, 
325608) antibody and analyzed with a FACS Aria II cytometer (Beckton Dickinson, San 
Jose, CA, USA) to guarantee that monocyte contamination was <0.5% (Fig. S5). Viability 












Flow cytometry.  
To determine the level of SLAMF1 membrane expression on neutrophils, cells stimulated 
with Mtb-Ag (10 μg/ml) were blocked in PBS (137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 
2 mM KH2PO4, pH 7.4)-FBS 5% for 15 min and then stained for surface expression with 
fluorophore-marked antibodies against SLAMF1 (BD, 559572) before and after culture.  
Intracellular staining of endogenous saponin-resistant LC3 was performed as 
described [46]. Briefly, neutrophils were washed with PBS and then permeabilized with PBS 
containing 0.05% saponin (Sigma-Aldrich, 47036). In this protocol, the cells are not fixed, 
therefore LC3-I is washed out of the cell because, unlike LC3-II, it is not anchored to the 
autophagosome [46]. Cells were then incubated with mouse anti-human LC3A/B antibody 
(MBL International, M152-3) for 20 min, rinsed with PBS, incubated with anti-mouse 
secondary antibody conjugated to fluorescein isothiocyanate (eBioscience, 62-6511) for 20 
min and rinsed twice with PBS. Negative control samples were incubated with irrelevant 
isotype-matched monoclonal antibody (Biolegend, 400140). Samples were analyzed on a 
FACSAria II flow cytometer (BD Biosciences). 
Confocal microscopy.  
Treated neutrophils (seeded on poly-L-lysine coated coverslips) were fixed and 
permeabilized (cold methanol, 20 min) and stained with LC3B (Cell Signaling Technology, 
2775) and/or SLAMF1 primary antibodies and then with the corresponding secondary 
antibodies (Alexa Fluor® 488 Goat Anti-Rabbit IgG, Abcam, 150077; Alexa Fluor® 555 
Donkey Anti-Mouse IgG, Invitrogen, A31570). Nuclei were counterstained with DAPI. The 
coverslips were mounted with PBS-mowiol (Sigma-Aldrich, 81381) and imaged using an 
Olympus FV100 confocal microscope (objective 60/NA1.42, Olympus, Tokyo, Japan).  











All the images were processed using ImageJ software (Wayne Rasband, National Institutes of 
Health). After the image binarization using a defined threshold, the number of LC3 puncta 
was quantified using the Particle Analyzer plugin. Brightness and contrast were adjusted in 
all images belonging to the same individual, when needed. 
ROS measurement.  
Neutrophils from HD were incubated with 2’,7’-dichlorofluorescin diacetate (DCFDA, 50 
µM; Invitrogen, D399) during 15 min at 37°C. Then, cells were washed and stimulated with 
or without Mtb-Ag (10 µg/ml) ± a SLAMF1 agonist antibody (anti-SLAMF1, 10 µg/ml) for 
60 min. Finally, 2’,7’-dichlorofluorescin fluorescence was evaluated to monitor ROS 
production by flow cytometry. 
Statistical analysis.  
Analysis of variance and post hoc Tukey’s multiple comparisons test were used as indicated 
in the figure legend. Mann-Whitney U test and Wilcoxon rank sum test were used for the 
analysis of unpaired and paired samples respectively. Correlations were calculated using the 
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Figure 1. Neutrophil counts according to clinical and immunological parameters of 
tuberculosis patients. Neutrophil numbers per mm3 in blood from TB patients recruited at 
Hospital Muñiz, Buenos Aires. Each dot represents the number of neutrophils (per mm3) for 
each individual, analyzed according to: (A) the severity of the TB disease as determined by 
the radiological lesions (Severe, n=88; Moderate, n=48; Mild, n=14); (B) an immunological 
classification based on in vitro lymphocyte responses to Mtb-Ag [15] (HR, High responder, 
n=65 ; and LR Low responder TB patients, n=97); (C) Acid-fast bacilli (AFB) in sputum 
smear (Ziehl-Neelsen staining; BAAR-, n=13; BAAR+, n=88; BAAR++, n=24; BAAR+++, 
n=37); (D) Time of disease evolution (months with clinical symptoms previous to hospital 
admission of the individual; one month or less, n=58; more than one month, n=104). 
Statistical differences were calculated using the nonparametric Mann-Whitney test for 
unpaired samples. n.s., not significant differences. * p <0.05; ** p <0.01; One-way ANOVA 
with post hoc Dunnett’s multiple comparisons test; Correlation factor (r) and P were 
calculated using the nonparametric Spearman correlation test.  
 
Figure 2. Expression of SLAMF1 in human neutrophils. Neutrophils from HD and TB 
patients were stimulated with or without Mtb-Ag (10 µg/ml) during different times, and 
SLAMF1 expression was determined by (A) confocal microscopy and (B, C, D) flow 
cytometry. (A) Neutrophils from TB patients were stimulated ± Mtb-Ag during 2 h. 
Representative images from ten independent experiments are shown. Scale bars: 5 μm. (B) 
Kinetics of SLAMF1 surface expression as measured by flow cytometry. Each point 
represents the mean values of the percentage of SLAMF1+ neutrophils ± SEM at 0, 2, 4 or 16 
h after Mtb-Ag stimulation (n=5). (C) SLAMF1 surface expression in neutrophils from HD 











of the percentage of SLAMF1+ neutrophils ± SEM (left axis) and dots represent the number 
of SLAMF1 neutrophils/10,000 cells (right axis). (D) A representative histogram of flow 
cytometry is shown. Statistical differences were calculated using the Wilcoxon signed rank 
test for paired samples. * p <0.05, ** p <0.01.  # p <0.05; Mann-Whitney nonparametric test 
for unpaired samples. 
 
Figure 3. Mechanisms of induction of SLAMF1 expression in humans. (A) Human purified 
neutrophils from HD (n=12) donors were stimulated either with Mtb-Ag (10 µg/ml), total 
Mtb lipids, purified protein derivative (PPD, 10 µg/ml), ESAT-6 (10 µg/ml), CFP-10 (10 
µg/ml), ManLam (10 µg/ml) or 19kDa lipoprotein (10 µg/ml) during 2 h. Finally, SLAMF1 
surface expression was evaluated by flow cytometry as previously described. (B) Neutrophils 
from HD (n=7) were pre-incubated with PD98059 (50µM), an MEK1/ERK MAPK inhibitor, 
or with SB202190 (10µM), a MAPK14/p38 inhibitor, for 30 min. Cells were then stimulated 
with or without Mtb-Ag (10 µg/ml) during 2 h. Afterwards SLAMF1 surface expression was 
determined by flow cytometry. (C) Neutrophils from HD (n=4) were stimulated with or 
without Mtb-Ag (10 µg/ml) in the presence or absence of diphenyleneiodonium (DPI, 10 µM) 
during 2 h. Afterwards, SLAMF1 surface expression was determined by flow cytometry. (A, 
B, C) Bars represent the mean values of the percentage of SLAMF1+ neutrophils ± SEM. 
Statistical differences were calculated using one-way ANOVA and post hoc Dunnett multiple 
comparison test. * p <0.05, **p<0.01, ***p<0.001.      
 
Figure 4. Role of SLAMF1 in neutrophil autophagy. (A) Neutrophils from HD (n=12) and 
TB patients (n=13) were stimulated with or without Mtb-Ag (10 µg/ml) during 2 h, and 
intracellular saponin-resistant LC3A/B-II determination was performed by flow cytometry. 











without Mtb-Ag (10 µg/ml) and treated with a SLAMF1 agonist antibody (anti-SLAMF1, 10 
µg/ml). Then, autophagy levels in neutrophils were evaluated by (B) immunofluorescence 
against LC3B in neutrophils (n=4) and (C) flow cytometry against intracellular saponin-
resistant LC3A/B-II (n=16). (D) Before autophagy determination, bafilomycin A1 (Baf A1) 
(100 nM) was added for the last 60 min of culture. Then, autophagy levels in neutrophils 
were evaluated by immunofluorescence against LC3B. Bars represent the mean values of 
LC3 puncta per cell ± SEM. (E) Fluorescence distribution of SLAMF1 and LC3B in Mtb-Ag-
stimulated neutrophils. Neutrophils were fixed after 1 h of Ag stimulation. Then, cells were 
permeabilized and stained using specific antibodies anti-SLAMF1 (red) and anti-LC3B 
(green). Images were acquired with a confocal microscope. Representative images of one out 
of five TB patients are shown. (A, C) Bars represent the mean values of the percentage of 
LC3A/B-II+ neutrophils ± SEM. (B, D) Representative images of one experiment are shown. 
Scale bars: 5 μm. Statistical differences were calculated using one-way ANOVA and post hoc 
Dunnett multiple comparison test. ** p <0.01, *** p <0.001, **** p <0.0001. # p <0.05; 
Mann-Whitney nonparametric test for unpaired samples.  
 
Figure 5. SLAMF1 ligation increases ROS levels in human neutrophils. (A) Neutrophils 
from HD (n=8) were incubated with 2’,7’-dichlorofluorescein diacetate (DCFDA, 50 µM) 
during 15 min and then stimulated with or without Mtb-Ag (10 µg/ml) ± an SLAMF1 agonist 
antibody (anti-SLAMF1, 10 µg/ml) during 60 min. Finally, DCFDA fluorescence was 
evaluated to monitor ROS production by flow cytometry. Left panel: Bars represent the mean 
values of the mean fluorescence intensity (MFI) of neutrophils of 8 HD ± SEM. Right panel: 
a representative histogram is shown (Control: non-stained cells). (B) Neutrophils from HD 
(n=5) were stimulated or not with Mtb-Ag (10 µg/ml) ± a SLAMF1 agonist antibody (anti-











inhibitor, for 2 h. Then, neutrophil autophagy levels were evaluated by intracellular saponin-
resistant LC3A/B-II immunostaining and analyzed by flow cytometry. Bars represent the 
mean values of the percentage of LC3A/B-II+ neutrophils ± SEM. No statistical differences 
were found between Mtb-Ag-stimulated neutrophils treated with DPI compared to Mtb-Ag-
stimulated cells treated with both anti-SLAMF1 and DPI. Statistical differences were 
calculated using one-way ANOVA and post hoc Dunnett multiple comparison test. * p <0.05 
** p <0.01. 
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